Home » Archive by Category

News

Original content and news from BioSpace, Xconomy, Marketwire and other sources, specific to the region.

West Coast Biotech Roundup: Onyx, Calico, Otonomy, Dendreon & More

August 14, 2014 – 11:35 am | Edit Post
West Coast Biotech Roundup: Onyx, Calico, Otonomy, Dendreon & More

[Corrected 8/14/14, 8:11pm. See below.] When Amgen (NASDAQ: AMGN) bought South San Francisco-based Onyx Pharmaceuticals last year for $10.4 billion, it expected great things from Onyx’s…

[[Click headline to continue reading.]]

Internship program participant aims high

August 14, 2014 – 10:18 am | Edit Post
Internship program participant aims high

Xavier University of Louisiana student Kirk McCall might seem like your average college student: energetic, full of potential, and harboring big dreams for the future. But Kirk is also working on sophisticated one-of-a-kind science experiments during his four-summer internship program at Sanford-Burnham and has accumulated lab experience years ahead of most of his peers. When we

Read More

Genetic signal prevents immune cells from turning against the body

August 13, 2014 – 5:00 pm | Edit Post

LA JOLLA–When faced with pathogens, the immune system summons a swarm of cells made up of soldiers and peacekeepers. The peacekeeping cells tell the soldier cells to halt fighting when invaders are cleared. Without this cease-fire signal, the soldiers, known as killer T cells, continue their frenzied attack and turn on the body, causing inflammation and autoimmune disorders such as allergies, asthma, rheumatoid arthritis, multiple sclerosis and type 1 diabetes.

Genetic signal prevents immune cells from turning against the body

August 13, 2014 – 5:00 pm | Edit Post

LA JOLLA–When faced with pathogens, the immune system summons a swarm of cells made up of soldiers and peacekeepers. The peacekeeping cells tell the soldier cells to halt fighting when invaders are cleared. Without this cease-fire signal, the soldiers, known as killer T cells, continue their frenzied attack and turn on the body, causing inflammation and autoimmune disorders such as allergies, asthma, rheumatoid arthritis, multiple sclerosis and type 1 diabetes.

Otonomy Hears Wall Street Ovation as Some Life Sciences IPOs Dim

August 13, 2014 – 4:23 pm | Edit Post
Otonomy Hears Wall Street Ovation as Some Life Sciences IPOs Dim

Auris Medical, the Swiss biotech focused on diseases and disorders of the ear, got the catchy ticker symbol (NASDAQ: EARS) when it went public last week. But San Diego biotech ear specialist  Otonomy…

[[Click headline to continue reading.]]

Otonomy Hears Wall Street Ovation as Some Life Sciences IPOs Dim

August 13, 2014 – 4:23 pm | Edit Post
Otonomy Hears Wall Street Ovation as Some Life Sciences IPOs Dim

Auris Medical, the Swiss biotech focused on diseases and disorders of the ear, got the catchy ticker symbol (NASDAQ: EARS) when it went public last week. But San Diego’s Otonomy (NASDAQ: OTIC)…

[[Click headline to continue reading.]]

Otonomy Hears Wall Street Ovation as Some Life Sciences IPOs Dim

August 13, 2014 – 4:23 pm | Edit Post
Otonomy Hears Wall Street Ovation as Some Life Sciences IPOs Dim

Auris Medical, the Swiss biotech focused on diseases and disorders of the ear, got the catchy ticker symbol (NASDAQ: EARS) when it went public last week. But San Diego’s Otonomy (NASDAQ: OTIC)…

[[Click headline to continue reading.]]

Shares Rise After Otonomy’s $100M IPO

August 13, 2014 – 4:08 pm | Edit Post

Shares of Otonomy Inc. were rising Aug. 13 after the biotech drug developer’s initial public offering raised $100 million.

New Blood: Tracing the Beginnings of Hematopoietic Stem Cells

August 13, 2014 – 2:36 pm | Edit Post
New Blood: Tracing the Beginnings of Hematopoietic Stem Cells

In a paper published online this week in Nature, researchers at the University of California, San Diego School of Medicine elaborate upon a crucial signaling pathway and the role of key proteins, which may help clear the way to generate …

Otonomy completes $100 million IPO

August 13, 2014 – 9:37 am | Edit Post

San Diego developer of ear disease drugs sells $6.25 million shares for $16 each.